JNJ · News · 20261015N

Strategic Investment Portfolio

JOHNSON & JOHNSON · 2026-10-15 · Importance 34 · Surprise 42

Johnson & Johnson Innovation - JJDC, Inc. and Johnson & Johnson reported beneficial ownership of 1,475,302 TRex Bio shares. The holding represented 5.3% of TRex Bio’s common stock after its October 13, 2026 IPO. The filing attributed shared voting and dispositive power to JJDC and Johnson & Johnson.

Key facts

• The Schedule 13G filing states Johnson & Johnson Innovation - JJDC, Inc. and Johnson & Johnson have shared voting and dispositive power over the 1,475,302 TRex Bio shares. source
• Johnson & Johnson Innovation - JJDC, Inc. and its parent company, Johnson & Johnson, filed a Schedule 13G indicating beneficial ownership of 1,475,302 shares of TRex Bio, Inc.'s common stock. source
• The 1,475,302 shares represent 5.3% of the class based on shares outstanding after TRex Bio's IPO on October 13, 2026, per the filing. source
• Jim Cramer provided analysis and discussed Johnson & Johnson on the 'Squawk on the Street' video segment. source
• Johnson & Johnson is listed among five blue-chip companies highlighted as reliable dividend payers in the article. source